Loading stock data…
VKTX
$28.02-1.22 (-4.16%)
Market OpenUpdated 1:31 PM EDT
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viking Therapeutics, Inc. in the Healthcare sector is trading at $28.02. Wall Street consensus targets $92.58 (19 analysts), implying a +230.5% move over the next 12 months. The stock is currently 35% below its 52-week high of $43.15, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +230.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$164.13M↑ | -$164.74M↓ | -$98.56M↓ | -$74.57M↓ | -$55.47M |
| Net Income | -$158.32M↓ | -$157.66M↓ | -$90.79M↓ | -$65.56M↓ | -$45.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-94.11%
Volume
Today's trading volume
1.45M
Recent News
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.
Should Viking’s VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?
Viking Therapeutics recently highlighted its obesity program at the 46th Annual William Blair Growth Stock Conference in Chicago and outlined plans to advance VK2735, including both injectable and oral formulations, toward pivotal trials. A key focus is the upcoming Phase 1 maintenance trial readout for VK2735 in the third quarter, which could clarify how flexible dosing regimens might support sustained weight management with fewer side effects and inform the design of late-stage...
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside
Data readout from the maintenance dosing study of VK2735, the company’s investigational obesity candidate, is expected in the third quarter.
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
An upcoming trial result could change how investors think about the weight-loss drug market.